While it is largely unknown whether Sox9 participates in potential cross-talks with other cancer-driving pathways and whether Sox9 play distinct roles dependent upon the molecular subtypes of glioma, our study highlights the function of Sox9 as an oncogenic transcription factor, and has implications for targeted therapy and prognostic assessment of clinical gliomas. The gene discussed is SOX9; the disease is central nervous system cancer.